Pfizer
NEWS
BioSpace talked with Paul Mango, one of the key leaders of Operation Warp Speed, about the experience.
Shares of Sanofi took a hit in premarket trading after it announced its Phase II breast cancer study assessing an experimental oral SERD failed to hit the mark.
Pfizer will cease operations within Russia and proceeds from its subsidiary in that country will be donated to provide direct humanitarian support to the people of Ukraine.
A new study out of Duke University added weight to the determination that asthma in children did not increase infection risk, children slow to get COVID vaccine and more COVID-19 news.
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
The death toll related to COVID-19 is more than 6 million, according to the Johns Hopkins COVID-19 dashboard, but it has long been suspected that the toll is significantly higher.
The Business Research Company (TBRC), a market research and intelligence firm, released a promising analysis of the global psoriatic arthritis treatment market.
Bancel reaped the rewards of SpikeVax’s success, but the Boston Business Journal noted that annual compensation for Moderna’s median employee plunged 16%.
Pfizer has launched a Phase II/III study to assess its oral antiviral Paxlovid in non-hospitalized symptomatic pediatric patients who are at risk for progression to serious disease.
JOBS
IN THE PRESS